Funding round
eGenesis Series D
eGenesis, which works in xenotransplantation solutions development in Cambridge, raised $191M in a Series D round announced on 4 Sep 2024, led by Lux Capital. 11 firms took part, 6 of them already investors. It is eGenesis' fourth venture round on record; the one before was a Series C in Mar 2021.
$191M
Amount raised
Not disclosed
Post-money valuation
11
Investors
1 lead
Valuation
What this round says about the price
eGenesis did not disclose a valuation in this round. It came 42 months after eGenesis' Series C. It is 42% of the $454M eGenesis has raised in the venture rounds on record. No later venture round is on record for eGenesis.
eGenesis' funding rounds
eGenesis has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Lux Capital led the round with 10 other firms. ARCH Venture Partners, Khosla Ventures, Farallon and Alta Partners and 2 more had backed eGenesis before.
Lead investor
- Lux Capital backs 194 venture-backed companies new investor
Also in the round
- ARCH Venture Partners backs 99 venture-backed companies existing investor
- Khosla Ventures backs 396 venture-backed companies existing investor
- backs 15 venture-backed companies existing investor
- backs 18 venture-backed companies existing investor
- Fresenius Medical Care Ventures existing investor
- Leaps by Bayer existing investor
- DaVita new investor
- backs 7 venture-backed companies new investor
- NATCO Pharmaceuticals new investor
- Parkwood Corporation new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
12 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $138M, and this round was 1.4 times the median. The closest in time, other companies' Series D rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Element Biosciences Biotechnology | 10 Jul 2024 | $277M | $1.03B | Wellington Management |
| Biotechnology | 12 Nov 2024 | $181M | not disclosed | OrbiMed and Novo Holdings |
| Biotechnology | 16 Jul 2024 | $150M | not disclosed | Canaan and Bioqube Ventures |
| Biotechnology | 5 Nov 2024 | $34M | not disclosed | Seer, Inc. |
| Biotechnology | 12 Mar 2025 | $35M | not disclosed | RA Capital |
| Biotechnology | 3 Mar 2025 | $700K | not disclosed | not named |
| Pathos Biotechnology | 15 May 2025 | $365M | $1.60B | not named |
| Biotechnology | 24 Jun 2025 | $97M | not disclosed | healthcare investor |
Sources
Where this comes from
Reported by 8 sources.
Questions
Frequently asked
How much did eGenesis raise in its Series D round?
eGenesis raised $191M in its Series D round, announced in Sep 2024.
Who led eGenesis' Series D round?
Lux Capital led it, with ARCH Venture Partners, Khosla Ventures, Farallon, Alta Partners and Fresenius Medical Care Ventures and 5 more.
What was eGenesis' valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Biotechnology?
12 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $138M, and this round was 1.4 times the median.